| Discovery research: the scientific challenge of finding new antibiotics DM Livermore, ... Journal of antimicrobial chemotherapy 66 (9), 1941-1944, 2011 | 365 | 2011 |
| Cost-effectiveness of malaria diagnostic methods in sub-Saharan Africa in an era of combination therapy S Shillcutt, C Morel, C Goodman, P Coleman, D Bell, CJM Whitty, A Mills Bulletin of the World Health Organization 86, 101-110, 2008 | 317 | 2008 |
| International cooperation to improve access to and sustain effectiveness of antimicrobials C Årdal, K Outterson, SJ Hoffman, A Ghafur, M Sharland, N Ranganathan, ... The Lancet 387 (10015), 296-307, 2016 | 207 | 2016 |
| Cost effectiveness analysis of strategies to combat malaria in developing countries CM Morel, JA Lauer, DB Evans Bmj 331 (7528), 1299, 2005 | 193 | 2005 |
| WHO global research priorities for antimicrobial resistance in human health S Bertagnolio, Z Dobreva, CM Centner, ID Olaru, D Donà, S Burzo, ... The Lancet Microbe 5 (11), 2024 | 178 | 2024 |
| The urgent need for new antibacterial agents R Wise, ... Journal of antimicrobial chemotherapy 66 (9), 1939-1940, 2011 | 165 | 2011 |
| Stoking the antibiotic pipeline CM Morel, E Mossialos Bmj 340, 2010 | 163 | 2010 |
| Policies and incentives for promoting innovation in antibiotic research E Mossialos, CM Morel, S Edwards, J Berenson, M Gemmill-Toyama, ... World Health Organization. Regional Office for Europe, 2010 | 157 | 2010 |
| Antibiotic research and development: business as usual? S Harbarth, U Theuretzbacher, J Hackett, Drive-AB Consortium, ... Journal of Antimicrobial Chemotherapy 70 (6), 1604-1607, 2015 | 124 | 2015 |
| Mapping global policy discourse on antimicrobial resistance D Wernli, PS Jørgensen, CM Morel, S Carroll, S Harbarth, N Levrat, ... BMJ Global Health 2 (2), e000378, 2017 | 121 | 2017 |
| Conquering malaria JG Breman, A Mills, RW Snow, JA Mulligan, C Lengeler, K Mendis, ... | 121 | 2011 |
| Industry incentives and antibiotic resistance: an introduction to the antibiotic susceptibility bonus CM Morel, O Lindahl, S Harbarth, MEA de Kraker, S Edwards, A Hollis The Journal of antibiotics 73 (7), 421-428, 2020 | 114 | 2020 |
| Human resources estimates and funding for antibiotic stewardship teams are urgently needed C Pulcini, CM Morel, E Tacconelli, B Beovic, K De With, H Goossens, ... Clinical Microbiology and Infection 23 (11), 785-787, 2017 | 101 | 2017 |
| Effective antibacterials: at what cost? The economics of antibacterial resistance and its control AR White, ... Journal of antimicrobial chemotherapy 66 (9), 1948-1953, 2011 | 89 | 2011 |
| A threshold analysis of the cost-effectiveness of artemisinin-based combination therapies in sub-saharan Africa PG Coleman, C Morel, SAM Shillcutt, C Goodman, AJ Mills The Intolerable Burden of Malaria II: What's New, What's Needed: Supplement …, 2004 | 83 | 2004 |
| A one health framework to estimate the cost of antimicrobial resistance CM Morel, RA Alm, C Årdal, A Bandera, GM Bruno, E Carrara, ... Antimicrobial Resistance & Infection Control 9 (1), 187, 2020 | 73 | 2020 |
| The economics of malaria in pregnancy—a review of the evidence and research priorities E Worrall, C Morel, S Yeung, J Borghi, J Webster, J Hill, V Wiseman, ... The Lancet infectious diseases 7 (2), 156-168, 2007 | 73 | 2007 |
| Delinking investment in antibiotic research and development from sales revenues: the challenges of transforming a promising idea into reality K Outterson, U Gopinathan, C Clift, AD So, CM Morel, JA Røttingen PLoS medicine 13 (6), e1002043, 2016 | 62 | 2016 |
| Building a multisystemic understanding of societal resilience to the COVID-19 pandemic D Wernli, M Clausin, N Antulov-Fantulin, J Berezowski, N Biller-Andorno, ... BMJ global health 6 (7), e006794, 2021 | 58 | 2021 |
| The Millennium Development Goals fail poor children: the case for equity-adjusted measures DD Reidpath, CM Morel, JW Mecaskey, P Allotey PLoS medicine 6 (4), e1000062, 2009 | 58 | 2009 |
Anne MillsVerified email at lshtm.ac.uk
